Pacira(PCRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved $726 million in revenue, marking a significant increase compared to previous years, with the highest gross margins in its history at 80% for Q4 2025, up from 79% in Q4 2024 [5][19] - The fourth quarter sales for EXPAREL increased to $155.8 million from $147.7 million in 2024, reflecting a volume growth of approximately 7% [18] - Non-GAAP R&D expenses rose to $34.4 million in Q4 2025 from $22.0 million in the previous year, while SG&A expenses increased to $91.9 million from $70.6 million [20] Business Line Data and Key Metrics Changes - EXPAREL's sales growth was driven by expanding patient and provider access, with a notable increase in coverage outside the surgical bundle, reaching 102 million lives by the end of 2025 [15][8] - ZILRETTA sales remained flat at $33 million in Q4 2025 compared to 2024, while ioveraê°™ sales grew to $7 million from $6.5 million [18] Market Data and Key Metrics Changes - The company reported a significant shift in payer coverage, with 102 million lives covered outside the surgical bundle, indicating a positive trend in reimbursement policies [15][8] - The strategic focus on key markets with high procedural volumes contributed to a collective volume growth of over 7% in these markets compared to 2024 [15] Company Strategy and Development Direction - The company is advancing its 5x30 strategy, aiming to help 3 million patients annually by 2030, with a clear focus on innovative, non-opioid pain management therapies [5][12] - Partnerships with J&J MedTech and LG Chem are expected to enhance market access and revenue growth, particularly in Asia Pacific [9][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving steady top-line growth in 2026, despite potential headwinds from a soft market for elective procedures [48][49] - The company anticipates a revenue guidance for 2026 of $745 million to $770 million, with EXPAREL sales projected between $600 million and $620 million [22] Other Important Information - The company has secured a volume-limited settlement with Fresenius, extending EXPAREL's exclusivity through 2039, and strengthened its IP estate to 21 patents [8] - The company executed $150 million in stock repurchases, reducing outstanding shares to approximately 41 million [21] Q&A Session Summary Question: What constitutes a clinically meaningful signal for the OA readout? - Management clarified that the primary focus of the PCRX-201 trial is safety, with secondary endpoints related to pain, stiffness, and function being evaluated [28][30] Question: What factors could lead to higher or lower guidance for EXPAREL? - Management highlighted the steady growth achieved in 2025 and the potential for upside or downside developments based on market conditions, particularly in elective procedures [37][39] Question: What are the headwinds affecting ZILRETTA's performance? - Management noted that prioritizing EXPAREL led to some disruption in ZILRETTA sales, but they expect clearer growth objectives for the partnership with J&J MedTech in 2026 [58][60]